Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

[1] Morales J(2014)Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases Crit Rev Eukaryot Gene Expr 24 15-28

[2] Li L(2013)The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol 14 882-892

[3] Fattah FJ(2016)Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer N Engl J Med 375 2154-2164

[4] Dong Y(2013)Impact of cardiovascular comorbidity on ovarian cancer mortality Cancer Epidemiol Biomark Prev 22 2102-2109

[5] Bey EA(2016)Elderly ovarian cancer patients: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Eur J Cancer 60 101-106

[6] Patel M(2014)Cardiac effects of anticancer therapy in the elderly J Clin Oncol 32 2654-2661

[7] Gao J(2018)Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives Oncotarget 9 25738-25749

[8] Boothman DA(2010)Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 14-25

[9] Sandhu SK(2018)Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs Cancer Treat Rev 63 135-143

[10] Schelman WR(2016)Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies Cancer Chemother Pharmacol 78 775-784

[1] Morales J(2014)Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases Crit Rev Eukaryot Gene Expr 24 15-28

[2] Li L(2013)The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol 14 882-892

[3] Fattah FJ(2016)Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer N Engl J Med 375 2154-2164

[4] Dong Y(2013)Impact of cardiovascular comorbidity on ovarian cancer mortality Cancer Epidemiol Biomark Prev 22 2102-2109

[5] Bey EA(2016)Elderly ovarian cancer patients: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Eur J Cancer 60 101-106

[6] Patel M(2014)Cardiac effects of anticancer therapy in the elderly J Clin Oncol 32 2654-2661

[7] Gao J(2018)Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives Oncotarget 9 25738-25749

[8] Boothman DA(2010)Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 14-25

[9] Sandhu SK(2018)Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs Cancer Treat Rev 63 135-143

[10] Schelman WR(2016)Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies Cancer Chemother Pharmacol 78 775-784